Navigation Links
PAREXEL Issues Updated Financial And Operational Information
Date:1/11/2010

remainder to be recorded in the second half of Fiscal Year 2010. The timing of the restructuring and related charges has been pushed out as a result of delays associated with local labor law compliance requirements.

For Fiscal Year 2010, consolidated service revenue is now expected to be in the range of $1.115 to $1.145 billion (previously issued revenue guidance was $1.105 to $1.125 billion). GAAP earnings per diluted share for Fiscal Year 2010 are now projected to be in the range of $0.60 and $0.70, and adjusted earnings per diluted share (excluding the previously mentioned restructuring and related charges) are expected to be in the range of $0.90 to $1.00 (previously issued GAAP diluted earnings per share guidance was $0.57 to $0.67, and adjusted diluted earnings per share was $0.87 to $0.97).

The Company expects to report a net book-to-bill ratio in the range of 1.25 for new business authorizations in the December 2009 quarter (net book-to-bill is defined as gross new business wins, less cancellations, divided by consolidated service revenue).

For Calendar Year 2010, consolidated service revenue is expected to be in the range of $1.170 to $1.215 billion, and GAAP earnings per diluted share are projected to be in the range of $0.85 to $1.00. Adjusted earnings per diluted share, (excluding the previously mentioned restructuring and related charges) are projected to be in the range of $1.00 to $1.15.

PAREXEL plans to report financial results for the second quarter on January 25, 2010, and to host a conference call regarding the results on January 26, 2010.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company includes certain non-GAAP financial measures in this press release. The Company believes that these non-GAAP financial measures assist investors and others in comparing the Company's results to previous period
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... leader, reports results for the second quarter of ... the group,s results and its performance in different ... transcript:  http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire ... - Q2 results - Performance drivers ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... LAUDERDALE, Fla., Feb. 25 The International,Confocal ... medical,professionals and students, has been formed as ... use of reflective confocal microscopy (RCM) in,patient ... and welcoming new members worldwide.,Dermatologists, dermascopists, dermatopathologists, ...
... Healthcare Real-Time Location System (RTLS) Market, ORLANDO, ... ), a leader in precision ultra wideband (UWB),real- ... Ultra Wideband System (PLUS) product line at the ... which employs,Time Domain,s patented UWB technology, enables RTLS ...
... Inc., a,global specialty pharmaceutical company, announced today that ... Aton,s parent company,Princeton Pharma Holdings LLC. Dr. Eshelman ... Product Development, Inc. (Nasdaq: PPDI ), an,international ... of Princeton Pharma Holdings LLC., "We are ...
Cached Biology Technology:International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy 2Time Domain Showcases Precision Location Capability of Ultra Wideband PLUS Product Line at HIMSS 2008 2Time Domain Showcases Precision Location Capability of Ultra Wideband PLUS Product Line at HIMSS 2008 3Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board 2
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... A study from scientists at Queen Mary, University of London, ... or go through major surgery, can suffer organ damage in ... injury. The study, published today in Nature Immunology ... move out of blood vessels to defend damaged organs against ...
... in Nature Photonics , U of T Engineering researchers report ... coatings that efficiently convert the sun,s rays to electricity. The ... first efficient tandem solar cell based on colloidal quantum dots (CQD). ... layers one tuned to capture the sun,s visible rays, the ...
... cover in the northern U.S. and into Canada as a factor ... new study by researchers at the University of Georgia indicates they ... It turns out that snow piling up over a band of ... effect on the climate of the U.S. as the much-better-known El ...
Cached Biology News:Rogue blood cells may contribute to post-surgery organ damage 2U of T researchers crack full-spectrum solar challenge 2Northern Eurasian snowpack could be a predictor of winter weather in US, team from UGA reports 2
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
Biology Products: